IL1B and chondrosarcoma: To assess whether we could characterize the therapeutic effect of the secretome of MSCs using our strategy, we co-cultured chondrosarcoma cells (SW1353) that were treated with a pro-inflammatory cytokine, interleukin 1 beta, to induce OA, with the MSCs expressing MetRSL274G (Figure 5A), and we profiled the secretome of the MSCs analyzing the secretome in terms of its ability to suppress OA (Table S1).